|
1
|
Winder T and Lenz HJ: Molecular predictive
and prognostic markers in colon cancer. Cancer Treat Rev.
36:550–556. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Anderson JC and Shaw RD: Update on colon
cancer screening: Recent advances and observations in colorectal
cancer screening. Curr Gastroenterol Rep. 16:4032014. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Karanikas M and Esebidis A: Increasing
incidence of colon cancer in patients <50 years old: A new
entity? Ann Transl Med. 4:1642016. View Article : Google Scholar :
|
|
4
|
Dinic J, Podolski-Renic A, Stankovic T,
Bankovic J and Pesic M: New approaches with natural product drugs
for overcoming multidrug resistance in cancer. Curr Pharm Des.
21:5589–5604. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Chazin EL, Reis RR, Junior WT, Moor LF and
Vasconcelos TR: An overview on the development of new potentially
active camptothecin analogs against cancer. Mini Rev Med Chem.
14:953–962. 2014. View Article : Google Scholar
|
|
6
|
Baird RD, Tan DS and Kaye SB: Weekly
paclitaxel in the treatment of recurrent ovarian cancer. Nat Rev
Clin Oncol. 7:575–582. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xie X, Tang B, Zhou J, Gao Q and Zhang P:
Inhibition of the PI3K/Akt pathway increases the chemosensitivity
of gastric cancer to vincristine. Oncol Rep. 30:773–782.
2013.PubMed/NCBI
|
|
8
|
Qin R, Shen H, Cao Y, Fang Y, Li H, Chen Q
and Xu W: Tetrandrine induces mitochondria-mediated apoptosis in
human gastric cancer BGC-823 cells. PLoS One. 8:e764862013.
View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Lin YC, Chang CW and Wu CR:
Anti-nociceptive, anti-inflammatory and toxicological evaluation of
Fang-Ji-Huang-Qi-Tang in rodents. BMC Complement Altern Med.
15:102015. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Ho LJ, Juan TY, Chao P, Wu WL, Chang DM,
Chang SY and Lai JH: Plant alkaloid tetrandrine downregulates
IkappaBalpha kinases-IkappaBalpha-NF-kappaB signaling pathway in
human peripheral blood T cell. Br J Pharmacol. 143:919–927. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Zhang J, Yu B, Zhang XQ, Sheng ZF, Li SJ,
Wang ZJ, Cui XY, Cui SY and Zhang YH: Tetrandrine, an
antihypertensive alkaloid, improves the sleep state of
spontaneously hypertensive rats (SHRs). J Ethnopharmacol.
151:729–732. 2014. View Article : Google Scholar
|
|
12
|
Kou B, Liu W, He W, Zhang Y, Zheng J, Yan
Y, Zhang Y, Xu S and Wang H: Tetrandrine suppresses metastatic
phenotype of prostate cancer cells by regulating Akt/mTOR/MMP-9
signaling pathway. Oncol Rep. 35:2880–2886. 2016.PubMed/NCBI
|
|
13
|
Lin Y, Wang Y and Liu X, Yan J, Su L and
Liu X: A novel derivative of tetrandrine (H1) induces endoplasmic
reticulum stress-mediated apoptosis and prosurvival autophagy in
human non-small cell lung cancer cells. Tumour Biol.
37:10403–10413. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Wu K, Zhou M, Wu QX, Yuan SX, Wang DX, Jin
JL, Huang J, Yang JQ, Sun WJ, Wan LH, et al: The role of IGFBP-5 in
mediating the anti-proliferation effect of tetrandrine in human
colon cancer cells. Int J Oncol. 46:1205–1213. 2015.
|
|
15
|
Zhang Y, Liu W, He W, Zhang Y, Deng X, Ma
Y, Zeng J and Kou B: Tetrandrine reverses epithelial-mesenchymal
transition in bladder cancer by downregulating Gli-1. Int J Oncol.
48:2035–2042. 2016.PubMed/NCBI
|
|
16
|
Wei N, Liu GT, Chen XG, Liu Q, Wang FP and
Sun H: H1, a derivative of Tetrandrine, exerts anti-MDR activity by
initiating intrinsic apoptosis pathway and inhibiting the
activation of Erk1/2 and Akt1/2. Biochem Pharmacol. 82:1593–1603.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Dang Y, Xu Y, Wu W, Li W, Sun Y, Yang J,
Zhu Y and Zhang C: Tetrandrine suppresses
lipopolysaccharide-induced microglial activation by inhibiting
NF-κB and ERK signaling pathways in BV2 cells. PLoS One.
9:e1025222014. View Article : Google Scholar
|
|
18
|
Meng LH, Zhang H, Hayward L, Takemura H,
Shao RG and Pommier Y: Tetrandrine induces early G1 arrest in human
colon carcinoma cells by down-regulating the activity and inducing
the degradation of G1-S-specific cyclin-dependent kinases and by
inducing p53 and p21Cip1. Cancer Res. 64:9086–9092. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
He BC, Gao JL, Zhang BQ, Luo Q, Shi Q, Kim
SH, Huang E, Gao Y, Yang K, Wagner ER, et al: Tetrandrine inhibits
Wnt/β-catenin signaling and suppresses tumor growth of human
colorectal cancer. Mol Pharmacol. 79:211–219. 2011. View Article : Google Scholar :
|
|
20
|
Bellomo C, Caja L and Moustakas A:
Transforming growth factor β as regulator of cancer stemness and
metastasis. Br J Cancer. 115:761–769. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Lampropoulos P, Zizi-Sermpetzoglou A,
Rizos S, Kostakis A, Nikiteas N and Papavassiliou AG: TGF-beta
signalling in colon carcinogenesis. Cancer Lett. 314:1–7. 2012.
View Article : Google Scholar
|
|
22
|
Zarzynska JM: Two faces of TGF-beta1 in
breast cancer. Mediators Inflamm. 2014:1417472014. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Ouhtit A, Madani S, Gupta I,
Shanmuganathan S, Abdraboh ME, Al-Riyami H, Al-Farsi YM and Raj MH:
TGF-β2: A novel target of CD44-promoted breast cancer invasion. J
Cancer. 4:566–572. 2013. View
Article : Google Scholar : PubMed/NCBI
|
|
24
|
Laverty HG, Wakefield LM, Occleston NL,
O'Kane S and Ferguson MW: TGF-beta3 and cancer: A review. Cytokine
Growth Factor Rev. 20:305–317. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu M, Trobridge P, Wang Y, Kanngurn S,
Morris SM, Knoblaugh S and Grady WM: Inactivation of TGF-β
signaling and loss of PTEN cooperate to induce colon cancer in
vivo. Oncogene. 33:1538–1547. 2014. View Article : Google Scholar
|
|
26
|
Slattery ML, Herrick JS, Lundgreen A and
Wolff RK: Genetic variation in the TGF-β signaling pathway and
colon and rectal cancer risk. Cancer Epidemiol Biomarkers Prev.
20:57–69. 2011. View Article : Google Scholar
|
|
27
|
Kim YH, Kim G, Kwon CI, Kim JW, Park PW
and Hahm KB: TWIST1 and SNAI1 as markers of poor prognosis in human
colorectal cancer are associated with the expression of ALDH1 and
TGF-β1. Oncol Rep. 31:1380–1388. 2014.PubMed/NCBI
|
|
28
|
Principe DR, DeCant B, Staudacher J,
Vitello D, Mangan RJ, Wayne EA, Mascariñas E, Diaz AM, Bauer J,
McKinney RD, et al: Loss of TGFβ signaling promotes colon cancer
progression and tumor-associated inflammation. Oncotarget. Jun
4–2016.Epub ahead of print.
|
|
29
|
Zunwen L, Shizhen Z, Dewu L, Yungui M and
Pu N: Effect of tetrandrine on the TGF-β-induced smad signal
transduction pathway in human hypertrophic scar fibroblasts in
vitro. Burns. 38:404–413. 2012. View Article : Google Scholar
|
|
30
|
Luo J, Deng ZL, Luo X, Tang N, Song WX,
Chen J, Sharff KA, Luu HH, Haydon RC, Kinzler KW, et al: A protocol
for rapid generation of recombinant adenoviruses using the AdEasy
system. Nat Protoc. 2:1236–1247. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Chen XL, Ren KH, He HW and Shao RG:
Involvement of PI3K/AKT/GSK3beta pathway in tetrandrine-induced G1
arrest and apoptosis. Cancer Biol Ther. 7:1073–1078. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Goldwasser F, Bae I, Fornace AJ Jr and
Pommier Y: Differential GADD45, p21CIP1/WAF1, MCL-1 and
topoisomerase II gene induction and secondary DNA fragmentation
after camptothecin-induced DNA damage in two mutant p53 human colon
cancer cell lines. Oncol Res. 8:317–323. 1996.PubMed/NCBI
|
|
33
|
Chen MC, Lee NH, Ho TJ, Hsu HH, Kuo CH,
Kuo WW, Lin YM, Tsai FJ, Tsai CH and Huang CY: Resistance to
irinotecan (CPT-11) activates epidermal growth factor
receptor/nuclear factor kappa B and increases cellular metastasis
and autophagy in LoVo colon cancer cells. Cancer Lett. 349:51–60.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Bhagya N and Chandrashekar KR: Tetrandrine
- A molecule of wide bioactivity. Phytochemistry. 125:5–13. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Watabe T and Miyazono K: Roles of TGF-beta
family signaling in stem cell renewal and differentiation. Cell
Res. 19:103–115. 2009. View Article : Google Scholar
|
|
36
|
Neuzillet C, Tijeras-Raballand A, Cohen R,
Cros J, Faivre S, Raymond E and de Gramont A: Targeting the TGFβ
pathway for cancer therapy. Pharmacol Ther. 147:22–31. 2015.
View Article : Google Scholar
|
|
37
|
Fabregat I, Fernando J, Mainez J and
Sancho P: TGF-beta signaling in cancer treatment. Curr Pharm Des.
20:2934–2947. 2014. View Article : Google Scholar
|
|
38
|
Smith AL, Robin TP and Ford HL: Molecular
pathways: Targeting the TGF-β pathway for cancer therapy. Clin
Cancer Res. 18:4514–4521. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Morrison CD, Parvani JG and Schiemann WP:
The relevance of the TGF-β Paradox to EMT-MET programs. Cancer
Lett. 341:30–40. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Mancino M, Strizzi L, Wechselberger C,
Watanabe K, Gonzales M, Hamada S, Normanno N, Salomon DS and Bianco
C: Regulation of human Cripto-1 gene expression by TGF-beta1 and
BMP-4 in embryonal and colon cancer cells. J Cell Physiol.
215:192–203. 2008. View Article : Google Scholar
|
|
41
|
Han S, Bui NT, Ho MT, Kim YM, Cho M and
Shin DB: Dexamethasone inhibits TGF-β1-induced cell migration by
regulating the ERK and AKT pathways in human colon cancer cells via
CYR61. Cancer Res Treat. 48:1141–1153. 2016. View Article : Google Scholar
|
|
42
|
Xu C, Liu W, Chen Z, Wang Y, Xiong Z and
Ji Y: Effect of prenatal tetrandrine administration on transforming
growth factor-beta1 level in the lung of nitrofen-induced
congenital diaphragmatic hernia rat model. J Pediatr Surg.
44:1611–1620. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Guerrero F, Herencia C, Almadén Y,
Martínez-Moreno JM, Montes de Oca A, Rodriguez-Ortiz ME,
Diaz-Tocados JM, Canalejo A, Florio M, López I, et al: TGF-β
prevents phosphate-induced osteogenesis through inhibition of BMP
and Wnt/β-catenin pathways. PLoS One. 9:e891792014. View Article : Google Scholar
|
|
44
|
Vo BT, Morton D Jr, Komaragiri S, Millena
AC, Leath C and Khan SA: TGF-β effects on prostate cancer cell
migration and invasion are mediated by PGE2 through activation of
PI3K/AKT/mTOR pathway. Endocrinology. 154:1768–1779. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Stipursky J, Francis D and Gomes FC:
Activation of MAPK/PI3K/SMAD pathways by TGF-β(1) controls
differentiation of radial glia into astrocytes in vitro. Dev
Neurosci. 34:68–81. 2012. View Article : Google Scholar
|
|
46
|
Ciuffreda L, Falcone I, Incani UC, Del
Curatolo A, Conciatori F, Matteoni S, Vari S, Vaccaro V, Cognetti F
and Milella M: PTEN expression and function in adult cancer stem
cells and prospects for therapeutic targeting. Adv Biol Regul.
56:66–80. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Dillon LM and Miller TW: Therapeutic
targeting of cancers with loss of PTEN function. Curr Drug Targets.
15:65–79. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Molinari F and Frattini M: Functions and
regulation of the PTEN gene in colorectal cancer. Front Oncol.
3:3262014. View Article : Google Scholar : PubMed/NCBI
|
